All Rankings

Top 100 Biotech Companies 2026

Private biotechnology and genomics companies, ranked by disclosed lifetime funding.

Known total funding for 100 of 100 ranked companies: $70.6B.

Showing top 100 matching companies · Ranked by total funding raised

Use company data through the API.
Example request
curl "https://indexed.vc/api/v1/companies?industries=Biotech,Genomics&operatingStatus=active&sort=total_funding_raised&order=desc&limit=100" -H "X-API-Key: YOUR_API_KEY"

The API has no company type filter, so public companies can appear; this list counts private companies only.

The API cannot leave out companies whose latest round is a grant; this list does.

Data from Indexed.vcUpdated

Methodology: up to 100 active companies matching this list's filters are ordered by disclosed total funding in USD. Companies whose latest round is one of: Grant are excluded. Totals include recorded grants and other qualifying funding, not just equity. Open a company profile for its funding summary and available detail. How this data is built.

51
Abcuro

Abcuro is a clinical-stage company developing Ulviprubart, a FIC anti-KLRG1 antibody in Ph2/3 piv...

Newton, United States51–200Biotech, Healthcare
Series DTotal funding$473.3MAug 2026
52
nChroma Bio

Genetic medicines company developing targeted in vivo delivery and engineered epigenetic silencer...

Boston, United States51–200Biotech, Genomics
Venture RoundTotal funding$470.0MDec 2024
53
Pathos

Pathos uses multimodal oncology data and AI to simulate clinical trials, identify responsive pati...

Chicago, United States51–200Artificial Intelligence, Biotech
Series DTotal funding$467.0MMay 2025
54
DNA Script

DNA Script develops the SYNTAX platform for enzymatic DNA synthesis, enabling labs to print high-...

Paris, France51–200Biotech, Synthetic Biology
Series CTotal funding$466.5MJan 2022
55
Science.xyz

Clinical-stage medical technology company developing neural-engineering implants and platforms to...

Alameda, United States51–200Biotech, Medtech
Series CTotal funding$457.0MMar 2026
56
Owkin

Owkin builds agentic AI scientists trained on multimodal patient data to help biopharma teams acc...

San Francisco, United States201–500Artificial Intelligence, Biotech
Corporate RoundTotal funding$445.2MJan 2023
57
OMass Therapeutics

Biotech company harnessing native mass spectrometry and chemistry to discover small molecule drug...

Oxford, United Kingdom11–50Biotech
Series CTotal funding$440.5MOct 2026
58
AdvanCell

AdvanCell develops targeted alpha radiopharmaceutical therapies, using its vertically integrated ...

Sydney, Australia11–50Biotech, Healthcare
Venture RoundTotal funding$439.4MJul 2026
59
Helix

Population genomics and viral surveillance company enabling health systems and public health orga...

San Mateo, United States201–500Biotech, Diagnostics
Series CTotal funding$435.0MJun 2021
60
Ollin Biosciences

Clinical-stage biopharmaceutical company dedicated to developing best-in-disease therapies for vi...

Austin, United States11–50Biotech, Healthcare
Series BTotal funding$430.0MJun 2026
61
RayzeBio

RayzeBio advances radiopharmaceutical therapies for people with cancer, developing targeted treat...

San Diego, United States201–500Biotech, Healthcare
Series CTotal funding$418.0MSep 2022
62
eGenesis

eGenesis engineers human-compatible donor organs using multiplex gene editing to advance cross-sp...

Cambridge, United States51–200Biotech, Healthcare
Series DTotal funding$416.0MSep 2024
63
Benchling

Benchling provides a cloud platform for life sciences R&D, helping scientific teams plan experime...

San Francisco, United States501–1000Biotech, SaaS
Series G+Total funding$412.0MNov 2021
64
Enzene Biosciences

Global biologics CDMO specializing in biosimilars development, manufacturing, and continuous biop...

Pune, India501–1000Biotech, Manufacturing
Private EquityTotal funding$412.0MDec 2025
65
Verdiva Bio

Verdiva Bio is a clinical-stage biopharmaceutical company focused on developing innovative therap...

London, United Kingdom11–50Life Sciences, Biotech
Series ATotal funding$411.0MJan 2025
66
Sonoma Biotherapeutics

Develops engineered regulatory T cell therapies to restore immune balance and treat autoimmune an...

Seattle, United States51–200Biotech, Life Sciences
Corporate RoundTotal funding$410.0MSep 2024
67
Soufflé Therapeutics

Biotechnology company developing cell-specific siRNA-based genetic medicines targeting skeletal m...

Watertown, United States51–200Biotech, Healthcare
Series BTotal funding$406.6MOct 2026
68
Leyden Labs

Leyden Labs is a clinical-stage biotech developing intranasal antibody sprays that block respirat...

Leiden, Netherlands11–50Biotech, Healthcare
Venture RoundTotal funding$401.6MJun 2026
69
ReCode Therapeutics

ReCode develops precision-delivery genetic medicines, including mRNA and gene correction therapie...

Menlo Park, United States51–200Biotech, Healthcare
Venture RoundTotal funding$390.0MSep 2025
70
Inotrem

French clinical-stage biopharmaceutical company developing TREM-1 inhibition therapies, including...

Paris, France11–50Biotech
Series CTotal funding$379.3MOct 2022
71
Formation Bio

Tech-native pharma company acquiring and developing clinical-stage assets via proprietary sourcin...

New York, United States51–200Artificial Intelligence, Biotech
Series DTotal funding$372.0MJun 2024
72
Tizona Therapeutics

Tizona Therapeutics translates novel scientific insights into first-in-class immunotherapies desi...

South San Francisco, United States11–50Biotech, Healthcare
Corporate RoundTotal funding$370.0MJul 2020
73
Human Longevity

Human Longevity combines genomic science with clinical care to detect disease before symptoms and...

San Diego, United States51–200Biotech
Series BTotal funding$369.8MAug 2024
74
Alentis Therapeutics

Alentis Therapeutics develops anti-Claudin-1 antibodies and antibody-drug conjugates for Claudin-...

Basel, Switzerland51–200Biotech, Drug Discovery
Series DTotal funding$365.9MNov 2024
75
Beacon Therapeutics

Clinical-stage ophthalmic gene therapy company developing AAV-based treatments for rare and preva...

London, United Kingdom51–200Biotech
Series CTotal funding$365.0MJan 2026